Rongcan Biotech
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Rongcan Biotech - overview
Established
2020
Location
Shanghai, -, China
Primary Industry
Biotechnology
About
Established in 2020 and based in Wuhu, China, Rongcan Biotech operates as a nucleic acid drug developer, dedicated to the development and industrialization of gene drugs. The company's core technical members graduated from MIT and Harvard Medical School. It has established a joint laboratory of drug slow-release technology with Shanghai Jiao Tong University School of Pharmacy and has cooperated with WuXi AppTec Group and HuiGene Therapeutics. In December 2023, Rongcan Biotech raised more than CNY 100 million in series A funding.
Rongcan Biotech has established a nucleic acid drug RTP R&D technology platform to research and develop mRNA and SiRNA drugs. The company's product pipelines cover drugs in respiratory, cardiovascular, and solid tumors, as well as mRNA vaccines for infectious diseases.
Current Investors
Spring Collection Assets Management, Lilly Asia Ventures, Wuxi AppTec Group
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Healthcare IT, Pharmaceuticals
Website
www.rc-rna.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.